COVID-19

Specifically related to the COVID-19 pandemic and/or impacts thereof.

FAQs: Provision of methadone and buprenorphine for the treatment of Opioid Use Disorder in the COVID-19 emergency

SAMHSA recognizes the challenges posed by the current COVID-19 situation and is providing the following guidance on the provision of methadone and buprenorphine for the treatment of Opioid Use Disorder in the COVID-19 emergency for Opioid Treatment Programs.